---
title: "OncoMed Pharmaceuticals, Inc. (OMED.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OMED.US.md"
symbol: "OMED.US"
name: "OncoMed Pharmaceuticals, Inc."
datetime: "2026-05-20T14:42:09.951Z"
locales:
  - [en](https://longbridge.com/en/quote/OMED.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OMED.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OMED.US.md)
---

# OncoMed Pharmaceuticals, Inc. (OMED.US)

## Company Overview

OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

| Item | Detail |
|------|--------|
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OMED.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OMED.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OMED.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OMED.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**